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Melanoma remains among the most lethal cancers and, in spite of great attempts that have been made to increase the life
span of patients with metastatic disease, durable and complete remissions are rare. Plants and plant extracts have long been
used to treat a variety of human conditions; however, in many cases, effective doses of herbal remedies are associated with
serious adverse effects. Curcumin is a natural polyphenol that shows a variety of pharmacological activities including anti-
cancer effects, and only minimal adverse effects have been reported for this phytochemical. The anti-cancer effects of curcu-
min are the result of its anti-angiogenic, pro-apoptotic and immunomodulatory properties. At the molecular and cellular level,
curcumin can blunt epithelial-to-mesenchymal transition and affect many targets that are involved in melanoma initiation and
progression (e.g., BCl2, MAPKS, p21 and some microRNAs). However, curcumin has a low oral bioavailability that may limit its
maximal benefits. The emergence of tailored formulations of curcumin and new delivery systems such as nanoparticles, lipo-
somes, micelles and phospholipid complexes has led to the enhancement of curcumin bioavailability. Although in vitro and in
vivo studies have demonstrated that curcumin and its analogues can be used as novel therapeutic agents in melanoma, curcu-
min has not yet been tested against melanoma in clinical practice. In this review, we summarized reported anti-melanoma
effects of curcumin as well as studies on new curcumin formulations and delivery systems that show increased bioavailability.
Such tailored delivery systems could pave the way for enhancement of the anti-melanoma effects of curcumin.
Plant extracts and their active compounds have long been
regarded as promising candidates to treat a variety of human
diseases; however, natural products or their synthetic ana-
logues may cause serious side-effects.1,2 Since natural products
generally show less toxicity than synthetic compounds, they
have been the subject of increasing research interest particu-
larly for the treatment of cancer and its complications.3,4 Cur-
cumin is a natural polyphenol extracted from the rhizomes of
the plant Curcuma longa L (turmeric).5,6 Mounting evidence
indicates that curcumin plays signiﬁcant roles in several bio-
logical processes and possesses several pharmacological prop-
erties which are beneﬁcial to the treatment of human diseases.
These pharmacological effects include antioxidant,7–10 anti-
inﬂammatory,3,11–13 lipid-modifying,14–17 anti-arthritic,10,18
cardio-protective,19,20 anti-ischemic,21 anti-depressant,6,22 anti-
diabetic,23 neuro-protective,24 cognition-enhancing25–28 and
anti-atherosclerotic5,29 properties. These studies conﬁrmed
that curcumin can affect various targets such as cytokines, pro-
tein kinases, multiple transcription factors, adhesion molecules,
inﬂammatory mediators and redox state enzymes.5,30
Melanoma arises from malfunctioning of normal melano-
cytes in the epidermis. In recent decades, the incidence of
melanomas has increased at an alarming rate, particularly in
Western populations where individuals tend to have lighter
skin color and thus less sun protection.31–33 Patients with
advanced malignancies have poor prognoses with average
survival times of 3–11 months.31 Many melanomas with early
diagnoses can be removed by surgical resection with no fur-
ther problems to the patient. However, melanomas
Key words: curcumin, melanoma, therapy, cancer
*H.M and G.N. contributed equally to this work
DOI: 10.1002/ijc.30224
History: Received 9 Jan 2016; Accepted 25 May 2016; Online 9 June
2016
Correspondence to: Amirhossein Sahebkar, Department of Medical
Biotechnology, School of Medicine, Mashhad University of Medical
Sciences, Mashhad, P.O. Box: 91779-48564, Iran, Tel.: 985138002288,
Fax: 985138002287; E-mail: sahebkara@mums.ac.ir, amir_saheb2000@
yahoo.com
M
in
i
R
ev
ie
w
Int. J. Cancer: 139, 1683–1695 (2016) VC 2016 UICC
International Journal of Cancer
IJC
notoriously have high metastatic potential, and once metasta-
sis occurs, they are very difﬁcult to treat.31,34 Therefore, the
search for novel therapies against melanoma is warranted.
Many studies introduced curcumin as a novel molecule that
can be used for the treatment of melanoma.35,36) These
reports have employed curcumin and its analogues using var-
ious delivery systems in melanoma therapy.36,37
With respect to the pharmacokinetic proﬁle of curcumin,
it has been observed that utilization of novel delivery systems
such as micelles and nano-particles could increase curcumin
bioavailability, thereby potentiating its anti-tumor effects in
melanoma. In addition, the expression of certain microRNAs,
known to inﬂuence many molecular and cellular processes,
can be altered by curcumin.38,39 This review summarizes the
ﬁndings of various studies on the utilization of curcumin in
melanoma therapy. Research on the tailored formulations
with novel drug delivery systems, and synthetic analogues of
curcumin are also discussed.
Curcumin as a Therapeutic Agent in Melanoma
For hundreds of years, turmeric has been utilized as a treat-
ment for conditions like inﬂammation, neoplasm, etc.3,5 In
recent years, molecular targets and various cellular and
molecular pathways that are affected by curcumin have been
evaluated and identiﬁed.5,40
Several studies on animals and humans have indicated
that curcumin can be safe at various doses.41,42 These reports
showed that curcumin could be tolerated even at very high
doses. Although obtaining high doses of curcumin in humans
is a problem, with the help of novel drug delivery systems,
the problem of using bulky doses could be resolved.43
In addition, various studies have indicated that even low
doses of curcumin have therapeutic effects against various
diseases.44
Low solubility and lack of a high systemic bioavailability
is regarded as a major problem in utilization of curcumin as
a therapeutic agent.45 Several studies have reported low or
undetectable plasma/tissue levels of free curcumin.46,47 How-
ever, it must be taken into account the metabolites and deg-
radation products of curcumin, like curcumin sulfate,
curcumin glucuronide and tetrahydrocurcumin possess signif-
icant and, in some cases, similar or stronger biological and
pharmacological activities compared with curcumin.48–50
Another proof for the activity of curcumin metabolites is the
biological activity of curcumin treated with alkali, which is
known to destabilize curcumin.51
Many studies have shown that in multi-factorial diseases
such as cancer, some agents that affect various cellular and
molecular targets may be of higher therapeutic value.5,30,52
Among these agents, curcumin shows suitable properties and
can affect different pathways in various diseases such as can-
cer.52,53 Melanoma is known as one of the important malig-
nancies that shows poor diagnosis and high resistance to
different treatment regimens. Mounting evidence indicates
that curcumin affects several molecular and cellular pathways
involved in melanoma pathogenesis such as MST1, JNK,
Foxo3, Bim-1, Mcl-1, BCl-2, Bax and JAK-2/STAT-354–56
making it a promising therapeutic agent to be used against
this type of cancer. Figure 1 shows various cellular and
molecular pathways inﬂuenced by curcumin in melanoma.
In a research, Bush et al.56 investigated the molecular path-
ways targeted by curcumin during apoptosis in human mela-
noma cells. They revealed that curcumin can induce cell death
in various melanoma cell lines with wild-type or mutant p53.
They also showed that curcumin induces apoptosis dose- and
time-dependently in melanoma cell lines. Their results
indicated that curcumin induced cell death via different path-
ways e.g., activation of caspases-3 and caspases-8 but not
caspase-9 via a membrane-mediated mechanism. In addition,
it was shown that curcumin could induce Fas receptor aggre-
gation in a FasL-independent manner.56 Previous studies
showed that suppression of receptor aggregation inhibited
curcumin-induced cell death. Some evidence revealed that
melanoma cells with mutant p53 show strong resistance to
conventional chemo-therapeutic agents.56Therefore, curcumin
might be able to overcome the chemo-resistance of these cells
and open new horizons in cancer therapy.
Zhang et al.57 investigated the effects of curcumin on the
migration, proliferation and invasiveness of human mela-
noma cells. In the referred study, A375 cells were cultured,
passaged and treated with different concentrations of curcu-
min. Different concentrations of curcumin induced signiﬁ-
cant changes in the morphology of A375 cells. The results
indicated that curcumin can signiﬁcantly inhibit the migra-
tion and invasion of A375 cells compared with the control
group. Curcumin (50, 25 and 12.5 mM) signiﬁcantly
decreased the number of A375 cells in the treated group. In
addition, the rates of apoptosis at the concentrations of 6.25
and 12.5 mM of curcumin were signiﬁcantly higher than
those of the control group. On the other hand, phosphoryla-
tion levels of STAT-3 and JAK-2 at the concentrations of 10
and 20 mM of curcumin were signiﬁcantly lower than those
in the control group. Bcl-2 protein expression at the concen-
trations of 1, 2.5, 5, 10 and 20 mM of curcumin was signiﬁ-
cantly lower compared with the control group. In this latter
study, curcumin showed various effects such as anti-
proliferative and pro-apoptotic activities on A375 cells, and
the inhibition of JAK-2/STAT-3 signaling pathway was sug-
gested as one of mechanisms through which curcumin exerts
its effects on this cell line.57
Philip et al. showed that osteopontin (OPN) induces
nuclear factor kappa B (NF-jB) through pro-matrix metallo-
proteinase 2 activation via IkappaB alpha/IKK signaling path-
ways which are downregulated by curcumin in a melanoma
mouse model.58 Their results indicated that curcumin could
inhibit NF-jBB-DNA binding, NF-jB transcriptional activity
and the OPN-induced translocation of p65. The authors
revealed that curcumin could inhibit OPN-induced cell
migration, extracellular matrix invasion and cell proliferation.
Also, curcumin can synergistically induce apoptotic
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morphological changes by OPN in melanoma cells. More-
over, curcumin suppresses OPN-induced tumor growth in
nude mice, and inhibits the activation of OPN-induced
tumor and the levels of pro-MMP-2 expression. Table 1 illus-
trates the effect of curcumin on melanoma reported by differ-
ent studies.58
An important mediator of the cell stress response is heat
shock protein 90 (Hsp90), which has been reported to be
upregulated in melanoma,59 and its inhibition, along with the
inhibition of Hsp70, has been reported to enhance the sensi-
tivity of melanoma cells to the anti-tumor effects of hyper-
thermia.60 Interestingly, there is evidence showing that
curcumin synergistically enhances the anti-tumor effect of
bortezomib in melanoma through inhibition of Hsp90
expression.61 Hemeoxygenase/biliverdin reductase (HO/BVR)
is another main component of the cell stress response.62,63
This system facilitates the degradation of heme which is toxic
if produced in excess or unbalanced under redox condi-
tions.64 Recently, it was found that HO/BVR system is upreg-
ulated in melanoma patients.65 Interestingly, among the
pharmacological effects of curcumin, enhancement of the cell
stress response was mediated through HO/BVR.66 Hence,
regulation of cell stress response could be regarded as a
potential mechanism curcumin may affect development and
progression of melanoma.
Parallel to the identiﬁcation of many anti-cancer effects of
curcumin, some studies have indicated that this agent could
cause potential adverse effects under speciﬁc conditions.67,68
There is some data showing that curcumin could induce
chromosomal alterations and DNA damage, both in vitro
and in vivo.69 However, Kurien and colleagues indicated that
curcumin does not bind or intercalate into DNA.70 It should
be noted that this binding could be caused by the solvent of
curcumin (e.g., organic solvents) rather than the compound
itself.70 Inhibition of several drug-metabolizing enzymes
including CYP3A4, glutathione-S-transferase and UDP and
UDP-glucuronyl transferase is another effect of curcumin
which may induce potential drug interactions.71 Although
such sporadic reports on the potential adverse effects of cur-
cumin exist and necessitate further evaluations, the trend in
Figure 1. Cellular and molecular pathways affected by curcumin in melanoma. MAPK: mitogenactivated protein kinase; STAT: signal trans-
ducer and activator of transcription; NF-jB: nuclear factor kappa-light chain-enhancer of activated B cells; PARP: poly(ADP-ribose) polymer-
ase. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Table 1. Effects of curcumin on melanoma as reported by various studies
Dose Target gene Effects
Model
(in vitro/in vivo/
human) Type of cell line Ref
0–80 mM mPTP Facilitating mPTP death
pathway
In vitro WM-115, B16 72
10, 20 mM JAK-2/STAT-3 Anti-proliferative and
pro-apoptotic
activities
In vitro A375 57
10 mM – Inhibition of prolifera-
tion and stimulation
of differentiation
In vitro B16F10 73
15 mM Mcl-1, Bcl-2, Bax,
caspase-8, Caspase-
3, NF-jB, p38, p53
Apoptosis induction In vitro A375, MV3, M14 74
30–40 lM caspase-3/7 Apoptosis induction In vitro B16F10 75
10 mM ERK/Akt Apoptosis induction In vitro A375 76
30–100 lM mPTP, ANT-1 Apoptosis induction In vitro WM-115 77
0.2–5 mg/ml caspases 8, 9, 3 Apoptosis induction In vitro G-361, A375 78
25 mm/ml MST1, JNK, Foxo3,
Bim-1
Apoptosis induction In vitro B16 and WM-115 79
2.5 mM MRP1, GSTM1 Apoptosis induction In vitro CAL1 80
< 5 mM – Decreasing cell growth In vitro B16-F10 81
50 mM – Inhibition of tumorigen-
esis and
angiogenesis
In vitro, in vivo B16F1, B16F10,
A375, SK-Mel-28
82
1025 M PDE1A Anti-proliferative effect In vitro B16F10 83
20 lM – Inhibition of
melanogenesis
In vitro B16F10 84
50 lM NFjB, MT1-MMP,
MMP-2
Inhibition of tumor
growth and decrease
migration
In vitro, in vivo B16F10 85
1.25–10 mM PI3K/Akt/GSK 3b, ERK,
p38 MAPK
Inhibits melanogenesis In vitro B16 86
High dose – Apoptosis induction In vitro G361, A375 87
100 mg/kg EphA2, PI3K, MMP-2,
MMP9
Inhibition of tumor
growth and vasculo-
genic mimicry
In vitro B16F10 88
10 mM Caspase 3, Caspase 9,
Bcl-XL, X-IA
Induce apoptosis In vitro B16, WM-115 89
10 mM MITF, MEK/ERK, PI3K/
Akt
Suppressive activity on
a-MSH-stimulated
melanogenesis
In vitro B16F10 90
10–30 mM caspase-9, caspase-3 Induce apoptosis In vitro M21, SP6.5 55
20 mM PRL-3 Inhibition of metastasis In vitro, in vivo B16, B16BL6 91
20 mM STAT1, STAT5, IFN-
alpha, IFN-gamma,
interleukin-2
Apoptosis induction In vitro A375, Hs294T 92
50 lM Akt, NF-jB, BclXL, Erk,
VEGF, cyclin D1
Blocks tumor formation In vitro, in vivo B16F10 93
– bcl-2, P53 Apoptosis induction In vivo B16 94
75 mM eIF2a, GADD 153,
aspases-3/7, Bcl-2
Apoptosis induction In vitro B16F10 95
50 lM COX-2, cyclin D1, NF-jB Apoptosis induction In vivo B16F10 96
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ﬁndings is in favor of the acceptable safety of this compound.
Moreover, conducted clinical trials of curcumin have shown
the safety of curcumin for human use, even in studies admin-
istering highly bioavailable preparations of curcumin. It is
also interesting to note that curcumin has been afﬁrmed with
a GRAS (generally recognized as safe) status by the US Food
and Drug Administration.
Curcumin Analogs as Powerful Tools in Melanoma
Therapy
Mounting evidence indicates that curcumin has multiple bio-
logical effects that make it a promising therapeutic candidate
to be used in the treatment of several diseases such as can-
cer.107 On the other hand, it was observed that this agent has
low oral bioavailability which led to the development of cur-
cumin analogues (such as DM-1, EF24, D6 and CDF) with
better anti-cancer effects and bioavailability.52 DM-1, one of
the curcumin analogues, has shown anti-tumor effects in var-
ious in vitro and in vivo models.107,108 It has been conﬁrmed
that this compound is not only a suitable anti-cancer agent
with anti-metastatic and anti-proliferative activities but also it
has minimal side effects on normal cells.109, 110 Table 2
shows various curcumin analogues that can be used in mela-
noma therapy.
Commercial curcuminoids include curcumin, demethoxy-
curcumin and bisdemethoxycurcumin. Most of the studies
assessing the effects of curcumin against melanoma have
been conducted with curcumin. Therefore, the impact of
demethoxy and bisdemethoxy analogues, which are known to
differ with curcumin in some properties,111 in reducing the
progression of melanoma remains to be clariﬁed. Four major
strategies that could be used to improve the pharmacokinetic
proﬁle and enhance the delivery of curcumin are (i) Lipo-
somes, micelles and phospholipid complexes; (ii) Glucuroni-
dation/metabolism interference via co-administration of
curcumin with adjuvants like piperine; (iii) Nanoparticles
and (iv) Emulsifying or dispersing agents. Below, some of the
studies on these forms of curcumin in melanoma are
summarized.
In a study, Lo et al. reported that two compounds namely,
1,7-bis(4-hydroxyphenyl)21,4,6-heptatrien-3-one (BHPHTO)
and bisdemethoxycurcumin (BDMC) can inhibit the prolifer-
ation of melanoma cells.112 Moreover, Fai~ao-Flores et al.
revealed that curcumin analogue DM-1, alone or in combina-
tion with dacarbazine (DTIC), shows anti-tumor effects as it
Table 1. Effects of curcumin on melanoma as reported by various studies (Continued)
Dose Target gene Effects
Model
(in vitro/in vivo/
human) Type of cell line Ref
30 mM c-myc, caspase-3 Apoptosis induction In vitro A375 97
6.1–7.7 mM NF-jB, IKK Antiproliferative and
apoptotic
In vitro C32, G-361, WM 266- 54
30 lM GSTP1, MRP1 Inhibition of the
multidrug resistance
In vitro A375 98
18, 27 lM – Inhibition of growth of
B16-R melanoma
In vitro, in vivo B16-R 99
15 lM MMP-2 Anti-metastatic In vitro B16
F10
100
50 lM iNOS, NF-jB Apoptosis and cell cycle
arrest
In vitro A375 101
2.6, 1.9 lM GST Inhibition of the
multidrug resistance
In vitro CAL1 102
Dependent manner Nm23, E-cadherin Anti-metastatic
properties
In vitro, in vivo B16F10 103
50, 100 mM OPN, NF-jB Apoptosis induction In vitro, in vivo B16F10 58
30 mM Caspases-3/8 Apoptosis induction In vitro MMAN, MMRU, RPEP,
PMWK, Sk-mel-2,
Sk-mel-5, Sk-mel-28
c, MEWO
56
125 mg/ml COX-I, COX-II Antioxidant and
anti-inflammatory
activities
In vitro SKMEL-28, M14,
UACC-62
104
25 mM GST Inhibition of the
multidrug resistance
In vivo IGR-39 105
200 nmol/kg – Inhibition of lung
metastasis
In vivo B16F10 106
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inhibited melanoma progression in a melanoma mouse
model.113 In addition, no toxicological changes were observed
in organs such as the spleen, kidneys, liver and lungs after
the administration of DM-1, either alone or in combination
with DTIC. DM-1 in combination with DTIC improved the
recovery from anemia induced by melanoma and immuno-
modulation. It was found that DM-1 alone and in combina-
tion with DTIC induces apoptosis via the cleavage of
caspase-8, 23 and 29. These results indicated that DM-1
shows therapeutic effects on melanoma via a preferential
intrinsic apoptotic pathway by decreasing Bcl-2/Bax ratio.113
In another study, Pisano et al. indicated that D6, a curcu-
min analogue, has anti-tumor activity against melanoma and
neuroblastoma cells.114 This study revealed that a,b-unsatu-
rated ketone D6 shows stronger therapeutic effects in inhibi-
ting melanoma growth in comparison with curcumin.
Various experiments were done in this study such as clono-
genic assay, TUNEL assay, annexin-V staining and caspases
activation assay, and PARP cleavage assay. These experiments
conﬁrmed that D6 is more effective in the treatment of mela-
noma and neuroblastoma when compared with curcumin.
Hence, this data suggested that D6 can be considered as a
good candidate for new therapies against neural crest-derived
tumors.114
Dahmke et al. reported that “deketene curcumin” shows
better therapeutic effects than curcumin on melanoma
cells.115 This form of curcumin could induce toxicity in
B78H1 melanoma cells that ﬁnally lead to G2 arrest. Their
results conﬁrmed that deketene curcumin can be used as an
anti-cancer agent that possesses better bioavailability than
curcumin.115
Novel Therapeutic Approaches for Curcumin
Targeting in Melanoma
Various studies on bio-distribution, absorption, elimination
and metabolism of curcumin have indicated that this agent
has rapid metabolism, poor absorption and rapid elimination
from the body. Therefore, low systemic bioavailability of oral
curcumin is known as a major limitation of its use.128 How-
ever, it should be considered that many of the metabolites
and degradation products of curcumin, possess strong biolog-
ical and pharmacological activities.48–50
Table 2. Various curcumin analogs in melanoma therapy
Type of curcumin Dose Target gene
Model (in vitro/
in vivo/human) Type of cell line Ref
Tetrahydrocurcumin Dependent manner – In vitro, in vivo B16F-10 116
Salicyl curcumin Dependent manner – In vitro, in vivo B16F-10 116
Curcumin III Dependent manner – In vitro, in vivo B16F-10 116
D6 17.5 mg/kg Caspase-3 and 7 In vitro, in vivo LB24, CN-MelA,
GR-Mel, WM266-4, 1
3443, M14
114
Curcumin ferrocenyl
derivatives
17.9 mM – In vitro B16 117
(2E,6E)22,6-bis
(2,5-Dimethoxybenzylidene)
cyclohexanone
50 lM tyrosinase, In vitro B16 118
Curcumin- 13c 20 lM FGF-R1, EGFR, Btk,
Mink, Ret, Itk
In vitro, in vivo B16F10 119
Curcumin- compound C5 0.71 lg/ml Tubulin polymerization
inhibitory
In vitro B16-F10 120
DM-1 5 lM TNF-R1, caspase 8 In vitro, in vivo B16F10, A375 113
DM-1 75 lM Mcl-1, Bcl-xL In vitro SK-MEL-5 and A375 121
FLLL32/62 2 lM or 4 lM STAT3 In vitro A375, HT144 Hs294T 122,123
D6 270 nM p53, PI3K/Akt, NF-jB In vitro, in vivo LB24Dagi 124
Gercumin II 250 lM – In vitro SK-MEL-28 125
Bisdemethoxycurcumin
(BDMC)
25–100 lM – In vitro A2058, B16-F10 112
Deketene curcumin 20 lM G2 arrest In vitro B78H1 115
Curcumin-biphenyl
derivatives
1, 10 mM – In vitro WM266, CN,
LB24Dagi, PNP
126
DM-1 83 lM Caspase-3, 28
and 29
In vitro, in vivo B16F10 35
NC 2067 2.0–2.4 lM – In vitro A375 127
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Several studies utilized different approaches to overcome
the aforementioned limitations. Using adjuvants can be a
suitable approach to block curcumin metabolic pathways and
improve its bioavailability.129 Various delivery systems such
as liposomes, nanoparticles, micelles and phospholipid com-
plexes have been proposed to improve the pharmacokinetic
properties of curcumin for cancer therapy. For example,
micelles and phospholipid complexes can improve the gastro-
intestinal absorption of curcumin which results in higher
plasma levels.129 Another strategy is to enhance the aqueous
solubility of curcumin. Recently, Kurien et al. reported
enhancement of the solubility of curcumin in water by 35
folds by heat under pressure. Interestingly, heat-solubilized
curcumin was shown to increase pharmacological effect of
curcumin in mice with systemic lupus erythematosus (SLE)
and Sj€ogren’s syndrome (SS).130 This ﬁnding is in line with
previous studies showing enhanced solubility and biological
activity of heat-treated curcumin.131–45 Table 3 illustrates
novel curcumin delivery systems used in melanoma therapy.
In a study, Lu et al. showed that curcumin micelles remodel
tumor microenvironment and enhance vaccination efﬁcacy in
a model of advanced melanoma. In this study, an amphi-
philic curcumin-based micelle (curcumin-PEG conjugate;
CUR-PEG) was intravenously administered to a mouse
model of melanoma.30 Their results indicated that CUR-PEG
and vaccine treatments have a stronger anti-tumor effect
compared with separate treatments. Their study showed that
utilization of combination therapy leads to signiﬁcant IFN-g
production (7-fold increase) and cytotoxic T cell response
(41.06 5.0% speciﬁc killing). Moreover, in the tumor micro-
environment, these therapies led to signiﬁcantly downregu-
lated levels of immunosuppressive factors including myeloid-
derived suppressor cells (MDSCs), T-reg cells and IL-6, while
increased CD81 T cell population. It has been observed that
some pro-inﬂammatory cytokines such as TNF-a and IFN-g
have different expressions in the tumor microenvironment.
The aforementioned combination therapies could switch
macrophage polarization to M1 phenotype and downregulate
the STAT3 pathway in the treated tumors. It was found that
CUR-PEG can improve the effects of immunotherapy in mel-
anoma. Novel generations of drug delivery systems such as
nanoparticle (NP) technology have provided promising solu-
tions to improve the bioavailability of therapeutic agents.
This delivery system will probably be suitable for hydropho-
bic agents like curcumin that have low aqueous solubility.30
In another study, the effect of dipeptide nanoparticles of
curcumin on melanoma was evaluated.133 A nonprotein
amino acid, a, b-dehydro-phenylalanine, was used to entrap
curcumin in the dipeptide NPs, and the anti-tumor effects of
dipeptide-curcumin NPs were assessed in cancer models in
vitro and in vivo. Using different dehydro-dipeptides, it was
found that methionine-dehydro-phenylalanine can be
regarded as a suitable dehydro-dipeptide for loading and
releasing curcumin. In the mentioned study, it was revealed
that loading curcumin in dipeptide NPs can improve its cel-
lular availability and solubility, increase its toxicity in various
cancer cell lines, and improve curcumin’s efﬁcacy in inhibi-
ting tumor growth in mice bearing melanoma tumor.
Curcumin-dipeptide NPs also showed enhanced in vitro and
in vivo chemotherapeutic effects compared with free unfor-
mulated curcumin. These delivery systems have several
advantages as they are highly biocompatible and easy to
make, and possess a suitable capacity of loading and releasing
curcumin. Moreover, curcumin’s cellular uptake is improved
with dipeptide NPs.133
In another study, Loch-Neckel et al. examined the effect
of orally administered chitosan-coated polycaprolactone NPs
containing curcumin on metastatic melanoma in the lungs.36
Their results indicated that curcumin could decrease cell via-
bility and induce apoptosis in B16F10 melanoma cells. They
found that curcumin signiﬁcantly reduces the expression of
metalloproteinases in melanoma cells. Several studies showed
that metalloproteinases are associated with the proliferation
and migration of melanoma cells. The utilization of chitosan-
coated NPs containing curcumin decreased pulmonary tumor
formation in a melanoma lung metastasis model. In addition,
histological analyses indicated a few small nodules of mela-
noma in lungs of mice treated with this system. Hence,
curcumin-containing chitosan-coated polycaprolactone NPs
may be a suitable system for the treatment of malignant
melanoma.36
Curcumin and MicroRNAs in Melanoma
MicroRNAs (miRNAs) are known as small and noncoding
RNAs that can suppress gene expression at post-
transcriptional levels via sequence-speciﬁc interactions with
the 3’-untranslated regions (UTRs) of cognate mRNA tar-
gets.(149,150 In addition, miRNAs are involved in the regula-
tion of various key cellular processes such as apoptosis,
proliferation, differentiation and development.1502153 Altera-
tions in miRNA expression have been observed in a number
of cancers, including melanoma. These alterations can arise
from either genetic or epigenetic changes.154 It has been sug-
gested that dietary components may modulate miRNA
expression.155 Few studies have investigated the effect of cur-
cumin on the expression of miRNAs in melanoma. Table 4
illustrates various miRNAs affected by curcumin in different
cancers.
Dahmke et al. revealed that curcumin intake can affect
miRNAs in murine melanoma. They indicated that miR-205-
5p was the most signiﬁcantly altered miRNA.38 This latter
study showed that oral administration of curcumin can inﬂu-
ence the miRNA signature of engrafting melanoma. Dahmke
et al. evaluated the effects of curcumin in a melanoma model,
which was established by the injection of murine B78H1 cells
in the ﬂank of C57BL/6 mice. Curcumin-containing diet
(4%) was administered two weeks prior to the injection of
tumor cells until the end of the experiment. The results indi-
cated that curcumin feeding signiﬁcantly decreases the
growth of the ﬂank tumors and substantially alters miRNA
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expression signature in tumors. For example, miR-205-5p
was expressed over 100 times higher in the treatment groups
compared with the control group. MiRNAs can have various
targets in melanoma cells. Western blot analyses indicated
that some targets such as proliferating cell nuclear antigen
(PCNA) and anti-apoptotic B-cell CLL/lymphoma 2 (Bcl-2)
were signiﬁcantly downregulated in the treatment groups.
This study proposed that there are alterations in the miRNA
expression in engrafting curcumin-treated melanoma and
miR-205-5p was the most signiﬁcantly altered miRNA.38
Diphenyldiﬂuoroketone (EF24) is known as a curcumin
analogue with anti-tumor effects that are mediated via induc-
ing apoptosis and arresting cell cycle. Zhang et al. investi-
gated the effect of EF24 on miR-33b in melanoma cells.156
They revealed that at noncytotoxic concentrations, EF24 is
able to suppress epithelial-to-mesenchymal transition (EMT)
Table 3. Novel curcumin delivery systems in melanoma therapy
Type of curcumin Dose Target gene
Model (in vitro/in
vivo/human) Type of cell line Ref
Curcuminbased
micelle
– IL-6, CCL2, TNF-a, IFN-g In vitro, in vivo B16F10 30
Curcumin -FAPac -
CpG
Indolamine-2,3-
dioxygenase
In vitro, in vivo B16 53
Curcumin- RGD-PEG-
PLA
– – In vitro B16 52
Chitosan-coatedlipo-
somes-containing
curcumin
2.5 lM – In vitro B16F10 134
Curcumin – ANPs 135
Methionine-dehydro-
phenylalanine-cur-
cumin NPs
30 lM – In vitro, in vivo B6F10 133
Curcumin-RGD-lpNPs 25 mg/kg – In vitro, in vivo B16 136
Curcumin-loaded SPC
liposomes
20 mg/kg – In vitro B16-F10 137
Curcumin- MBCSPs 500 lg/ml – In vitro, in vivo B16F10 138
Curcumin- b-
Cyclodextrin
14 lM – In vitro A375 139
Curcumin- b-
Cyclodextrin-gemini
surfactant
14 lM – In vitro A375 139
Chitosan-coated
nanoparticles con-
taining curcumin
100 mM MMP-2, MMP-9 In vitro, in vivo B16F10 36
Curcumin/magnetite
nanoparticles
66.0 lM – In vitro B16-F10 140
Curcumin – chitin
nanogels
0.1–1.0 mg/ml – In vitro A375 141
Curcumin – HP-b-CD 300 lg/ml G2/M stage In vitro B16-F10 142
Curcumin – PEO-PCL 10, 80 mM – In vitro, in vivo B16F10 143
Curcumin – Muc18 167–335 nM NF-jB In vitro, in vivo B16F10 144
Curcumin plus PDMP 10 lM PI3K/AKT In vitro WM-115 and B16 145
Curcumin-nano-
capsules
6 mg/kg – In vitro, in vivo B16-F10 146
EF-24-FFRmk-fVIIa 1.5 mM – In vitro RPMI-7951 147
Curcumin – XGO-b-
PCL
1–100 mM – In vitro B16F10 148
FAP: fibroblast activation protein; PEG-PLA: polyethylene glycol-polylactic acid; ANPs: albumin nanoparticles; NP: nanoparticle; SPC: soybean phos-
phatidylcholine; MBCSPs: magnetic-based core-shell particles; HP-b-CD: hydroxypropyl-b-cyclodextrin; PEO-PCL: poly(ethylene oxide)-b-poly(epsilon-
caprolactone); PDMP: 1-phenyl-2-decanoylamino-3-morpholino-1-propanol; FFRmk-fVIIa: EF-24-phenylalanine-phenylalanine argininechloromethyl
ketone-factor VIIa; XGO-b-PCL: xyloglucan-block-poly(‹-caprolactone).
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and cell motility of melanoma cell lines such as A375 and
Lu1205. In addition, EF24 suppressed HMGA2 expression at
mRNA and protein levels. MiR-33b can directly bind to 3’
untranslated region (3’-UTR) of HMGA2 and suppress its
expression. It was shown that miR-33b inhibition or HMGA2
over-expression reverts EF24-mediated suppression of EMT.
Moreover, EF24 modulates the focal adhesion assembly, Src,
FAK and RhoA activation, and HMGA2-dependent actin
stress ﬁber formation via targeting miR-33b. Hence, these
results propose that EF24 can suppress melanoma metastasis
by upregulating miR-33b and concomitantly decreasing
HMGA2 expression.156
Yang et al. conﬁrmed that EF24 targets NF-jB and
miRNA-21, and possesses a promising anti-tumor activity.39
EF24 has been reported to inhibit the NF-jB pathway in
DU145 human prostate cancer cells and B16 murine mela-
noma cells. Moreover, EF24 induced apoptosis in these cells
apparently via inhibiting miR-21 expression, and also
improved the expression of several miR-21 target genes, e.g.,
PDCD4 and PTEN. This molecule inhibited miR-21 expres-
sion and lung metastasis, prolonged animal survival and
increased the expression of miR-21 target genes in a mouse
model of melanoma. Moreover, EF24 enhanced the expres-
sion of potential tumor suppressor miRNAs and inhibited
the expression of oncogenic miRNAs, such as miR-21. These
ﬁndings proposed that EF24 shows anti-cancer activities via
regulating NF-jB pathway and miRNA expression.39
Conclusion
Melanoma, a malignant tumor of melanocytes, is one of the
most aggressive types of malignancies. Although melanoma
comprises <5% of all skin cancers, it is responsible for the
majority of skin cancer-related deaths. At early stages, mela-
noma can be treated by surgical resection; however, most
often it progresses to the invasive stage and does not respond
to conventional treatments largely due to the development of
multi-drug resistance. Hence, new therapies are required to
overcome the limitations of conventional therapies. Several
lines of evidence have indicated that curcumin affects key
pathways that are involved in different cancers such as mela-
noma. It seems that this molecule plays an important role in
cancer therapy. Several targets at the cellular and molecular
levels (e.g., signaling pathways, transcription factors and miR-
NAs) are affected by curcumin in melanoma. Hence, curcu-
min can be regarded as a promising agent in the treatment
of melanoma. Nevertheless, utilization of curcumin is associ-
ated with some limitations such as rapid metabolism, low
oral absorption and rapid elimination from the body. These
limitations may attenuate efﬁcacy and decrease the therapeu-
tic effects of curcumin. New formulations and novel delivery
systems have opened a new window into the landscape of
treatment of various diseases such as melanoma with curcu-
min. Finally, most of the evidence on the efﬁcacy of curcu-
min against melanoma and other types of cancer pertains to
preclinical studies. Although some clinical evidence exists
that favors the beneﬁts of curcumin supplementation in can-
cer patients,1682170 clinical evidence is still scarce and a thor-
ough outcome study is yet to be performed. Hence, clinical
proof-of-concept investigations are required to verify the
translational value of the reported anti-tumor effects of cur-
cumin in animal and cellular models of cancer. However, fur-
ther evidence from prospective clinical trials is required to
decipher the place of curcumin in the clinical management of
melanoma.
References
1. Yu T, Chen C, Sun Y, et al. ABT-737 sensitizes
curcumin-induced anti-melanoma cell activity
through facilitating mPTP death pathway. Bio-
chem Biophys Res Commun 2015; 286–91.
2. Thangapazham RL, Sharad S, Maheshwari RK.
Skin regenerative potentials of curcumin. Biofac-
tors 2013; 39:141–9.
3. Panahi Y, Saadat A, Beiraghdar F, et al. Adju-
vant therapy with bioavailability-boosted curcu-
minoids suppresses systemic inﬂammation and
improves quality of life in patients with solid
tumors: a randomized double-blind placebo-
controlled trial. Phytother Res 2014; 28:
1461–7.
4. Bar-Sela G, Epelbaum R, Schaffer M. Curcumin
as an anti-cancer agent: review of the gap
between basic and clinical applicationsCurr.
Med Chem 2010; 17:190–7.
5. Sahebkar A. Dual effect of curcumin in prevent-
ing atherosclerosis: the potential role of pro-
oxidant-antioxidant mechanisms. Nat Prod Res
2015; 29:491–2.
6. Esmaily H, Sahebkar A, Iranshahi M, et al. An
investigation of the effects of curcumin on anxi-
ety and depression in obese individuals: a
randomized controlled trial. Chin J Integr Med
2015; 21:332–8.
7. Sahebkar A, Mohammadi A, Atabati A, et al.
Curcuminoids modulate pro-oxidant-antioxidant
balance but not the immune response
to heat shock protein 27 and oxidized LDL
in obese individuals. Phytother Res 2013; 27:
1883–8.
8. Panahi Y, Sahebkar A, Amiri M, et al. Improve-
ment of sulphur mustard-induced chronic pruri-
tus, quality of life and antioxidant status by
curcumin: results of a randomised, double-blind,
placebo-controlled trial. Br J Nutr 2012; 108:
1272–9.
9. Panahi Y, Ghanei M, Hajhashemi A, et al.
Effects of curcuminoids-piperine combination
on systemic oxidative stress, clinical symptoms
and quality of life in subjects with chronic pul-
monary complications due to sulfur mustard: a
randomized controlled trial. J Diet Suppl 2016;
13:93–105.
10. Panahi Y, Alishiri GH, Parvin S, et al. Mitiga-
tion of systemic oxidative stress by curcumi-
noids in osteoarthritis: results of a randomized
controlled trial. J Diet Suppl 2016; 13:209–20.
11. Sahebkar A. Are curcuminoids effective C-
reactive protein-lowering agents in clinical prac-
tice? Evidence from a meta-analysis. Phytother
Res 2014; 28:633–42.
12. Panahi Y, Sahebkar A, Parvin S, et al. A
randomized controlled trial on the anti-
inﬂammatory effects of curcumin in patients
with chronic sulphur mustard-induced cutane-
ous complications. Ann Clin Biochem 2012; 49:
580–8.
13. Panahi Y, Hosseini MS, Khalili N, et al. Antioxi-
dant and anti-inﬂammatory effects of
curcuminoid-piperine combination in subjects
with metabolic syndrome: a randomized con-
trolled trial and an updated meta-analysis. Clin
Nutr 2015; 34:1101–8.
14. Sahebkar A. Curcuminoids for the management
of hypertriglyceridaemia. Nat Rev Cardiol 2014;
11:123
15. Sahebkar A. Low-density lipoprotein is a poten-
tial target for curcumin: novel mechanistic
insights. Basic Clin Pharmacol Toxicol 2014;
114:437–8.
16. Panahi Y, Khalili N, Hosseini MS, et al. Lipid-
modifying effects of adjunctive therapy with
curcuminoids-piperine combination in patients
with metabolic syndrome: results of a random-
ized controlled trial. Complement Ther Med
2014; 22:851–7.
17. Mohammadi A, Sahebkar A, Iranshahi M, et al.
Effects of supplementation with curcuminoids
M
in
i
R
ev
ie
w
1692 A new candidate for melanoma therapy
Int. J. Cancer: 139, 1683–1695 (2016) VC 2016 UICC
on dyslipidemia in obese patients: a randomized
crossover trial. Phytother Res 2013; 27:374–9.
18. Panahi Y, Rahimnia AR, Sharaﬁ M, et al. Cur-
cuminoid treatment for knee osteoarthritis: a
randomized double-blind placebo-controlled
trial. Phytother Res 2014; 28:1625–31.
19. Sahebkar A. Why it is necessary to translate
curcumin into clinical practice for the preven-
tion and treatment of metabolic syndrome? Bio-
Factors 2013; 39:197–208.
20. Swamy AV, Gulliaya S, Thippeswamy A, et al.
Cardioprotective effect of curcumin against
doxorubicin-induced myocardial toxicity in
albino rats. Indian J Pharmacol 2012; 44:73–7
21. Sahebkar A. Molecular mechanisms for curcu-
min beneﬁts against ischemic injury. Fertil Steril
2010; 94:e75–6.
22. Panahi Y, Badeli R, Karami GR, et al. Investiga-
tion of the efﬁcacy of adjunctive therapy with
bioavailability-boosted curcuminoids in major
depressive disorder. Phytother Res 2015; 29:17–
21.
23. Chuengsamarn S, Rattanamongkolgul S,
Luechapudiporn R, et al. Curcumin extract for
prevention of type 2 diabetes. Diabetes Care
2012; 35:2121–7.
24. Mythri RB, Bharath MM. Curcumin: a potential
neuroprotective agent in Parkinson’s disease.
Curr Pharm Des 2012; 18:91–9.
25. Sahebkar A. Autophagic activation: a key piece
of the puzzle for the curcumin-associated cogni-
tive enhancement? J Psychophar 2016; 30:93–4.
26. Jiang Z, Guo M, Shi C, et al. Protection against
cognitive impairment and modiﬁcation of epi-
leptogenesis with curcumin in a post-status epi-
lepticus model of temporal lobe epilepsy.
Neuroscience 2015; 310:362–71.
27. Cox KH, Pipingas A, Scholey AB. Investigation
of the effects of solid lipid curcumin on cogni-
tion and mood in a healthy older population.
J Psychophar 2015; 29:642–51.
28. Shakeri A, Sahebkar A. Optimized curcumin
formulations for the treatment of Alzheimer’s
disease: a patent evaluation. J Neurosci Res 2016;
94:111–3.
29. Hasan ST, Zingg JM, Kwan P, et al.
Curcumin modulation of high fat diet-induced
atherosclerosis and steatohepatosis in LDL
receptor deﬁcient mice. Atherosclerosis 2014;
232:40–51.
30. Lu Y, Miao L, Wang Y, et al. Curcumin micelles
remodel tumor microenvironment and enhance
vaccine activity in an advanced melanoma
model. Mol Ther 2016; 24:364–74.
31. Miller AJ, Mihm MC, Jr. Melanoma. N Engl J
Med 2006; 355:51–65.
32. Gray ES, Rizos H, Reid AL, et al. Circulating
tumor DNA to monitor treatment response and
detect acquired resistance in patients with meta-
static melanoma. Oncotarget 2015; 6:42008–18.
Dec 8;:-.
33. Uzarska M, Czajkowski R, Schwartz RA, et al.
Chemoprevention of skin melanoma: facts and
myths. Melanoma Res 2013; 23:426–33.
34. Akabane H, Sullivan RJ. The future of molecular
analysis in melanoma: diagnostics to direct
molecularly targeted therapy. Am J Clin Derma-
tol 2016; 17:1–10.
35. Faiao-Flores F, Quincoces Suarez JA, Fruet AC,
et al. Curcumin analog DM-1 in monotherapy
or combinatory treatment with dacarbazine as a
strategy to inhibit in vivo melanoma progres-
sion. PloS One 2015; 10:e0118702
36. Loch-Neckel G, Santos-Bubniak L, Mazzarino L,
et al. Orally administered chitosan-coated poly-
caprolactone nanoparticles containing curcumin
attenuate metastatic melanoma in the lungs.
J Pharm Sci 2015; 104:3524–34.
37. Nguyen TA, Friedman AJ. Curcumin: a novel
treatment for skin-related disorders. J Drugs
Dermatol 2013; 12:1131–7.
38. Dahmke IN, Backes C, Rudzitis-Auth J, et al.
Curcumin intake affects miRNA signature in
murine melanoma with mmu-miR-205-5p most
signiﬁcantly altered. PloS One 2013; 8:e81122
39. Yang CH, Yue J, Sims M, et al. The curcumin
analog EF24 targets NF-kappaB and miRNA-21,
and has potent anticancer activity in vitro and
in vivo. PloS One 2013; 8:e71130
40. Li XJ, Li YZ, Jin CT, et al. Curcumin induces
apoptosis by PTEN/PI3K/AKT pathway in
EC109 cells. Zhongguo Ying Yong Sheng Li Xue
Za Zhi 2015; 31:174–7.
41. Bhavani Shankar T, Shantha N, Ramesh H,
et al. Toxicity studies on turmeric (Curcuma
longa): acute toxicity studies in rats, guineapigs
and monkeys. Indian J Exp Biol 1980; 18:73–5.
42. Lao CD, Rufﬁn MT, Normolle D, et al. Dose
escalation of a curcuminoid formulation. BMC
Complement Altern Med 2006; 6:10
43. Zhang J, Tang Q, Xu X, et al. Development and
evaluation of a novel phytosome-loaded chitosan
microsphere system for curcumin delivery. Int J
Pharm 2013; 448:168–74.
44. Aggarwal BB, Harikumar KB. Potential thera-
peutic effects of curcumin, the anti-
inﬂammatory agent, against neurodegenerative,
cardiovascular, pulmonary, metabolic, auto-
immune and neoplastic diseases. Int J Biochem
Cell Biol 2009; 41:40–59.
45. Kurien BT, Singh A, Matsumoto H, et al.
Improving the solubility and pharmacological
efﬁcacy of curcumin by heat treatment. Assay
Drug Dev Technol 2007; 5:567–76.
46. Mancuso C, Siciliano R, Barone E. Curcumin
and Alzheimer disease: this marriage is not to
be performed. J Biol Chem 2011; 286:le3
47. Anand P, Kunnumakkara AB, Newman RA,
et al. Bioavailability of curcumin: problems and
promises. Mol Pharm 2007; 4:807–18.
48. Aggarwal BB, Deb L, Prasad S. Curcumin differs
from tetrahydrocurcumin for molecular targets,
signaling pathways and cellular responses. Mole-
cules 2015; 20:185–205.
49. Barone E, Calabrese V, Mancuso C. Ferulic acid
and its therapeutic potential as a hormetin for
age-related diseases. Biogerontology 2009; 10:97–
108.
50. Sultana R. Ferulic acid ethyl ester as a potential
therapy in neurodegenerative disorders. Biochim
Biophys Acta 2012; 1822:748–52.
51. Kurien BT, Scoﬁeld RH. Curcumin/turmeric
solubilized in sodium hydroxide inhibits HNE
protein modiﬁcation—an in vitro study.
J Ethnopharmacol 2007; 110:368–73.
52. Zhao L, Yang C, Dou J, et al. Development of
RGD-functionalized PEG-PLA micelles for
delivery of curcumin. J Biomed Nanotechnol
2015; 11:436–46.
53. Jiang GM, Xie WY, Wang HS, et al. Curcumin
combined with FAPalphac vaccine elicits effec-
tive antitumor response by targeting
indolamine-2,3-dioxygenase and inhibiting EMT
induced by TNF-alpha in melanoma. Oncotarget
2015; 6:25932–42.
54. Siwak DR, Shishodia S, Aggarwal BB, et al. Cur-
cumin-induced antiproliferative and proapop-
totic effects in melanoma cells are associated
with suppression of IkappaB kinase and nuclear
factor kappaB activity and are independent of
the B-Raf/mitogen-activated/extracellular signal-
regulated protein kinase pathway and the Akt
pathway. Cancer 2005; 104:879–90.
55. Lu C, Song E, Hu DN, et al. Curcumin induces
cell death in human uveal melanoma cells
through mitochondrial pathway. Curr Eye Res
2010; 35:352–60.
56. Bush JA, Cheung KJ, Jr, Li G. Curcumin induces
apoptosis in human melanoma cells through a
Fas receptor/caspase-8 pathway independent of
p53. Exp Cell Res 2001; 271:305–14.
57. Zhang YP, Li YQ, Lv YT, et al. Effect of curcu-
min on the proliferation, apoptosis, migration,
and invasion of human melanoma A375 cells.
Genet Mol Res 2015; 14:1056–67.
58. Philip S, Kundu GC. Osteopontin induces
nuclear factor kappa B-mediated promatrix
metalloproteinase-2 activation through I kappa
B alpha/IKK signaling pathways, and curcumin
(diferulolylmethane) down-regulates these path-
ways. J Biol Chem 2003; 278:14487–97.
59. McCarthy MM, Pick E, Kluger Y, et al. HSP90
as a marker of progression in melanoma. Ann
Oncol 2008; 19:590–4.
60. Miyagawa T, Saito H, Minamiya Y, et al. Inhibi-
tion of Hsp90 and 70 sensitizes melanoma cells
to hyperthermia using ferromagnetic particles
with a low Curie temperature. Int J Clin Oncol
2014; 19:722–30.
61. Fang BM, Jiang JH, Zhang XW, et al. Curcumin
enhances bortezomib treatment of myeloma by
inhibiting heat shock protein 90 expression.
Trop J Pharm Res 2015; 14:227–33.
62. Calabrese V, Guagliano E, Sapienza M, et al.
Redox regulation of cellular stress response in
aging and neurodegenerative disorders: role of
vitagenes. Neurochem Res 2007; 32:757–73.
63. Mancuso C, Scapagini G, Curro D, et al. Mito-
chondrial dysfunction, free radical generation
and cellular stress response in neurodegenerative
disorders. Front Biosci 2007; 12:1107–23.
64. Mancuso C, Santangelo R, Calabrese V. The
heme oxygenase/biliverdin reductase system: a
potential drug target in Alzheimer s disease.
J Biol Reg Homeos Ag 2012; 27:75–87.
65. Arena V, Pennacchia I, Guerriero G, et al. The
heme oxygenase/biliverdin reductase system in
skin cancers. J Biol Reg Homeos Ag 2014; 29:
259–64.
66. Calabrese V, Bates TE, Mancuso C, et al. Curcu-
min and the cellular stress response in free
radical-related diseases. Mol Nutr Food Res
2008; 52:1062–73.
67. Goodpasture C, Arrighi F. Effects of food sea-
sonings on the cell cycle and chromosome mor-
phology of mammalian cells in vitro with
special reference to turmeric. Food Cosmet Toxi-
col 1976; 14:9–14.
68. Giri A, Das SK, Talukder G, et al. Sister chro-
matid exchange and chromosome aberrations
induced by curcumin and tartrazine on mam-
malian cells in vivo. Cytobios 1989; 62:111–7.
69. Burgos-Moron E. Calderon-Monta~no JM,
Salvador J, et al. The dark side of curcumin. Int
J Cancer 2010; 126:1771–5.
70. Kurien BT, Dillon SP, Dorri Y, et al. Curcumin
does not bind or intercalate into DNA and a
M
in
i
R
ev
ie
w
Mirzaei et al. 1693
Int. J. Cancer: 139, 1683–1695 (2016) VC 2016 UICC
note on the gray side of curcumin. Int J Cancer
2011; 128:242–5.
71. Mancuso C, Barone E. Curcumin in clinical
practice: myth or reality? Trends Pharmacol Sci
2009; 30:333–4.
72. Yu T, Chen C, Sun Y, et al. ABT-737 sensitizes
curcumin-induced anti-melanoma cell activity
through facilitating mPTP death pathway. Bio-
chem Biophys Res Commun 2015; 464:286–91.
73. Wolnicka-Glubisz A, Nogal K, Zadlo A, et al.
Curcumin does not switch melanin synthesis
towards pheomelanin in B16F10 cells. Arch Der-
matol Res 2015; 307:89–98.
74. Jiang AJ, Jiang G, Li LT, et al. Curcumin indu-
ces apoptosis through mitochondrial pathway
and caspases activation in human melanoma
cells. Mol Biol Rep 2015; 42:267–75.
75. Oelkrug C, Lange CM, Wenzel E, et al. Analysis
of the tumoricidal and anti-cachectic potential
of curcumin. Anticancer Res 2014; 34:4781–8.
76. Chen J, Li L, Su J, et al. Synergistic apoptosis-
inducing effects on A375 human melanoma cells
of natural borneol and curcumin. PloS One
2014; 9:e101277
77. Qiu Y, Yu T, Wang W, et al. Curcumin-induced
melanoma cell death is associated with mito-
chondrial permeability transition pore (mPTP)
opening. Biochem. Biophys Res Commun 2014;
448:15–21.
78. Buss S, Dobra J, Goerg K, et al. Visible light is a
better co-inducer of apoptosis for curcumin-
treated human melanoma cells than UVA. PloS
One 2013; 8:e79748
79. Yu T, Ji J, Guo YL. MST1 activation by curcu-
min mediates JNK activation, Foxo3a nuclear
translocation and apoptosis in melanoma cells.
Biochem Biophys Res Commun 2013; 441:53–8.
80. Attaoua C, Vincent LA, Abdel Jaoued A, et al.
Differential involvement of glutathione S-
transferase mu 1 and multidrug resistance pro-
tein 1 in melanoma acquired resistance to vinca
alkaloids. Fundam Clin Pharmacol 2015; 29:62–
71.
81. Shiau RJ, Wu JY, Chiou SJ, et al. Effects of cur-
cumin on nitrosyl-iron complex-mediated DNA
cleavage and cytotoxicity. Planta Med 2012; 78:
1342–50.
82. Chakraborty G, Kumar S, Mishra R, et al. Sema-
phorin 3A suppresses tumor growth and metas-
tasis in mice melanoma model. PloS One 2012;
7:e33633
83. Abusnina A, Keravis T, Yougbare I, et al. Anti-
proliferative effect of curcumin on melanoma
cells is mediated by PDE1A inhibition that regu-
lates the epigenetic integrator UHRF1. Mol Nutr
Food Res 2011; 55:1677–89.
84. Park SY, Jin ML, Kim YH, et al. Aromatic-tur-
merone inhibits alpha-MSH and IBMX-induced
melanogenesis by inactivating CREB and MITF
signaling pathways. Arch Dermatol Res 2011;
303:737–44.
85. Prakash M, Kale S, Ghosh I, et al. Hyaluronan-
binding protein 1 (HABP1/p32/gC1qR) induces
melanoma cell migration and tumor growth by
NF-kappa B dependent MMP-2 activation
through integrin alpha(v)beta(3) interaction. Cell
Signal 2011; 23:1563–77.
86. Tu CX, Lin M, Lu SS, et al. Curcumin inhibits
melanogenesis in human melanocytes. Phytother
Res 2012; 26:174–9.
87. Chatterjee SJ, Pandey S. Chemo-resistant mela-
noma sensitized by tamoxifen to low dose cur-
cumin treatment through induction of apoptosis
and autophagy. Cancer Biol Ther 2011; 11:216–
28.
88. Chen LX, He YJ, Zhao SZ, et al. Inhibition of
tumor growth and vasculogenic mimicry by cur-
cumin through down-regulation of the EphA2/
PI3K/MMP pathway in a murine choroidal mel-
anoma model. Cancer Biol Ther 2011; 11:229–
35.
89. Sun D, Zhuang X, Xiang X, et al. A novel nano-
particle drug delivery system: the anti-
inﬂammatory activity of curcumin is enhanced
when encapsulated in exosomes. Mol Ther 2010;
18:1606–14.
90. Lee JH, Jang JY, Park C, et al. Curcumin sup-
presses alpha-melanocyte stimulating hormone-
stimulated melanogenesis in B16F10 cells. Int J
Mol Med 2010; 26:101–6.
91. Wang L, Shen Y, Song R, et al. An anticancer
effect of curcumin mediated by down-regulating
phosphatase of regenerating liver-3 expression
on highly metastatic melanoma cells. Mol Phar-
macol 2009; 76:1238–45.
92. Bill MA, Bakan C, Benson DM, Jr, et al. Curcu-
min induces proapoptotic effects against human
melanoma cells and modulates the cellular
response to immunotherapeutic cytokines. Mol
Cancer Ther 2009; 8:2726–35.
93. Purkayastha S, Berliner A, Fernando SS, et al.
Curcumin blocks brain tumor formation. Brain
Res 2009; 1266:130–8.
94. Gui F, Ma WF, Cai SH, et al. Preliminary study
on molecular mechanism of curcumine anti-
mouse melanoma. Zhongyaocai 2008; 31:1685–9.
95. Bakhshi J, Weinstein L, Poksay KS, et al. Cou-
pling endoplasmic reticulum stress to the cell
death program in mouse melanoma cells: effect
of curcumin. Apoptosis 2008; 13:904–14.
96. Marin YE, Wall BA, Wang S, et al. Curcumin
downregulates the constitutive activity of NF-
kappaB and induces apoptosis in novel mouse
melanoma cells. Melanoma Res 2007; 17:274–83.
97. Qiu S, Tan SS, Zhang JA, et al. Apoptosis
induced by curcumin and its effect on c-myc
and caspase-3 expressions in human melanoma
A375 cell line. Di 1 Jun Yi Da Xue Xue
Bao5Academic Journal of the First Medical
College of PLA 2005; 25:1517–21.
98. Depeille P, Cuq P, Passagne I, et al. Combined
effects of GSTP1 and MRP1 in melanoma drug
resistance. Br J Cancer 2005; 93:216–23.
99. Odot J, Albert P, Carlier A, et al. In vitro and in
vivo anti-tumoral effect of curcumin against
melanoma cells. Int J Cancer 2004; 111:381–7.
100. Banerji A, Chakrabarti J, Mitra A, et al. Effect of
curcumin on gelatinase A (MMP-2) activity in
B16F10 melanoma cells. Cancer Lett 2004; 211:
235–42.
101. Zheng M, Ekmekcioglu S, Walch ET, et al. Inhi-
bition of nuclear factor-kappaB and nitric oxide
by curcumin induces G2/M cell cycle arrest and
apoptosis in human melanoma cells. Melanoma
Res 2004; 14:165–71.
102. Depeille P, Cuq P, Mary S, et al. Glutathione S-
transferase M1 and multidrug resistance protein
1 act in synergy to protect melanoma cells from
vincristine effects. Mol Pharmacol 2004; 65:897–
905.
103. Ray S, Chattopadhyay N, Mitra A, et al. Curcu-
min exhibits antimetastatic properties by modu-
lating integrin receptors, collagenase activity,
and expression of Nm23 and E-cadherin.
J Environ Pathol Toxicol Oncol 2003; 22:49–58.
104. Ramsewak RS, DeWitt DL, Nair MG. Cytotoxic-
ity, antioxidant and anti-inﬂammatory activities
of curcumins I-III from Curcuma longa. Phyto-
medicine 2000; 7:303–8.
105. Iersel ML, Ploemen JP, Struik I, et al. Inhibition
of glutathione S-transferase activity in human
melanoma cells by alpha, beta-unsaturated car-
bonyl derivatives. Effects of acrolein, cinnamal-
dehyde, citral, crotonaldehyde, curcumin,
ethacrynic acid, and trans-2-hexenal. Chem Biol
Interact 1996; 102:117–32.
106. Menon LG, Kuttan R, Kuttan G. Inhibition of
lung metastasis in mice induced by B16F10 mel-
anoma cells by polyphenolic compounds. Cancer
Lett 1995; 95:221–5.
107. Sharma RA, Gescher AJ, Steward WP. Curcu-
min: the story so far. Eur J Cancer 2005; 41:
1955–68.
108. Shishodia S, Sethi G, Aggarwal BB. Curcumin:
getting back to the roots. Ann N Y Acad Sci
2005; 1056:206–17.
109. Chen JW, Tang YL, Liu H, et al. Anti-prolifera-
tive and anti-metastatic effects of curcumin on
oral cancer cells. WCJS 2011; 29:83–6
110. Waghela BN, Sharma A, Dhumale S, et al. Cur-
cumin conjugated with PLGA potentiates sus-
tainability, anti-proliferative activity and
apoptosis in human colon carcinoma cells. PloS
One 2015; 10:e0117526
111. Anand P, Thomas SG, Kunnumakkara AB, et al.
Biological activities of curcumin and its ana-
logues (Congeners) made by man and mother
nature. Biochem Pharmacol 2008; 76:1590–611.
112. Lo CY, Liu PL, Lin LC, et al. Antimelanoma
and antityrosinase from Alpinia galangal constit-
uents. Scientiﬁc World J 2013; 2013:186505
113. Faiao-Flores F, Suarez JA, Maria-Engler SS,
et al. The curcumin analog DM-1 induces apo-
ptotic cell death in melanoma. Tumour 2013;
34:1119–29.
114. Pisano M, Pagnan G, Dettori MA, et al.
Enhanced anti-tumor activity of a new
curcumin-related compound against melanoma
and neuroblastoma cells. Mol Cancer 2010; 9:
137
115. Dahmke IN, Boettcher SP, Groh M, et al. Cook-
ing enhances curcumin anti-cancerogenic activ-
ity through pyrolytic formation of “deketene
curcumin”. Food Chem 2014; 151:514–9.
116. Leyon PV, Kuttan G. Studies on the role of
some synthetic curcuminoid derivatives in the
inhibition of tumour speciﬁc angiogenesis. J Exp
Clin Cancer Res 2003; 22:77–83.
117. Arezki A, Chabot G, Quentin L, et al. Synthesis
and biological evaluation of novel ferrocenyl
curcuminoid derivatives. Med Chem Commun
2011; 2:190–5.
118. Hosoya T, Nakata A, Yamasaki F, et al. Curcu-
min-like diarylpentanoid analogues as melano-
genesis inhibitors. J Nat Med 2012; 66:166–76.
119. Lamoral-Theys D, Wauthoz N, Heffeter P, et al.
Trivanillic polyphenols with anticancer cytostatic
effects through the targeting of multiple kinases
and intracellular Ca21 release. J Cell Mol Med
2012; 16:1421–34.
120. Ruan BF, Lu X, Li TT, et al. Synthesis, biological
evaluation and molecular docking studies of
resveratrol derivatives possessing curcumin moi-
ety as potent antitubulin agents. Bioorg Med
Chem 2012; 20:1113–21.
121. Faiao-Flores F, Suarez JA, Soto-Cerrato V, et al.
Bcl-2 family proteins and cytoskeleton changes
M
in
i
R
ev
ie
w
1694 A new candidate for melanoma therapy
Int. J. Cancer: 139, 1683–1695 (2016) VC 2016 UICC
involved in DM-1 cytotoxic effect on melanoma
cells. Tumour Biol 2013; 34:1235–43.
122. Bill MA, Fuchs JR, Li C, et al. The small mole-
cule curcumin analog FLLL32 induces apoptosis
in melanoma cells via STAT3 inhibition and
retains the cellular response to cytokines with
anti-tumor activity. Mol Cancer 2010; 9:165
123. Bill MA, Nicholas C, Mace TA, et al. Structur-
ally modiﬁed curcumin analogs inhibit STAT3
phosphorylation and promote apoptosis of
human renal cell carcinoma and melanoma cell
lines. PloS One 2012; 7:e40724
124. Rozzo C, Fanciulli M, Fraumene C, et al. Molec-
ular changes induced by the curcumin analogue
D6 in human melanoma cells. Mol Cancer 2013;
12:37
125. Valiahdi SM, Iranshahi M, Sahebkar A. Cyto-
toxic activities of phytochemicals from Ferula
species. DARU 2013; 21:39
126. Dettori MA, Fabbri D, Pisano M, et al. 4-substi-
tuted-2-methoxyphenol: suitable building block
to prepare new bioactive natural-like hydroxy-
lated biphenyls. Lett Drug Des Discov 2015; 12:
131–9.
127. Poorghorban M, Das U, Alaidi O, et al. Charac-
terization of the host-guest complex of a curcu-
min analog with beta-cyclodextrin and beta-
cyclodextrin-gemini surfactant and evaluation of
its anticancer activity. Int J Nanomedicine 2015;
10:503–15.
128. Kidd PM. Bioavailability and activity of phyto-
some complexes from botanical polyphenols: the
silymarin, curcumin, green tea, and grape seed
extracts. Altern Med Rev 2009; 14:226–46.
129. Prasad S, Tyagi AK, Aggarwal BB. Recent devel-
opments in delivery, bioavailability, absorption
and metabolism of curcumin: the golden pig-
ment from golden spiceCancer. Res Treat 2014;
46:2–18.
130. Kurien BT, Harris VM, Quadri SM, et al. Signif-
icantly reduced lymphadenopathy, salivary gland
inﬁltrates and proteinuria in MRL-lpr/lpr mice
treated with ultrasoluble curcumin/turmeric:
increased survival with curcumin treatment.
Lupus Sci Med 2015; 2:e000114
131. Kurien BT, Scoﬁeld RH. Oral administration of
heat-solubilized curcumin for potentially
increasing curcumin bioavailability in experi-
mental animals. Int J Cancer 2009; 125:1992–3.
132. Kurien BT, Scoﬁeld RH. Heat-solubilized curcu-
min should be considered in clinical trials for
increasing bioavailability. Clin Cancer Res 2009;
15:747
133. Alam S, Panda JJ, Chauhan VS. Novel dipeptide
nanoparticles for effective curcumin delivery. Int
J Nanomedicine 2012; 7:4207–22.
134. Karewicz A, Bielska D, Loboda A, et al. Curcu-
min-containing liposomes stabilized by thin
layers of chitosan derivatives. Colloids Surf B
Biointerfaces 2013; 109:307–16.
135. Cui M, Naczynski DJ, Zevon M, et al. Multi-
functional albumin nanoparticles as combination
drug carriers for intra-tumoral chemotherapy.
Adv Healthc Mater 2013; 2:1236–45.
136. Zhao Y, Lin D, Wu F, et al. Discovery and in
vivo evaluation of novel RGD-modiﬁed lipid-
polymer hybrid nanoparticles for targeted drug
delivery. Int J Mol Sci 2014; 15:17565–76.
137. Chen Y, Wu Q, Zhang Z, et al. Preparation of
curcumin-loaded liposomes and evaluation of
their skin permeation and pharmacodynamics.
Molecules 2012; 17:5972–87.
138. Wadajkar AS, Bhavsar Z, Ko CY, et al. Multi-
functional particles for melanoma-targeted drug
delivery. Acta Biomater 2012; 8:2996–3004.
139. Michel D, Chitanda JM, Balogh R, et al. Design
and evaluation of cyclodextrin-based delivery
systems to incorporate poorly soluble curcumin
analogs for the treatment of melanoma. Eur J
Pharm Biopharm 2012; 81:548–56.
140. de Souza FF, dos Santos MC, dos Passos DC,
et al. Curcumin associated magnetite nanopar-
ticles inhibit in vitro melanoma cell growth.
J Nanosci Nanotechnol 2011; 11:7603–10.
141. Mangalathillam S, Rejinold NS, Nair A, et al.
Curcumin loaded chitin nanogels for skin cancer
treatment via the transdermal route. Nanoscale
2012; 4:239–50.
142. Sun Y, Du L, Liu Y, et al. Transdermal delivery
of the in situ hydrogels of curcumin and its
inclusion complexes of hydroxypropyl-beta-
cyclodextrin for melanoma treatment. Int J
Pharm 2014; 469:31–9.
143. Ma Z, Haddadi A, Molavi O, et al. Micelles of
poly(ethylene oxide)-b-poly(epsilon-caprolac-
tone) as vehicles for the solubilization, stabiliza-
tion, and controlled delivery of curcumin.
J Biomed Mater Res A 2008; 86:300–10.
144. Langone P, Debata PR, Dolai S, et al. Coupling
to a cancer cell-speciﬁc antibody potentiates
tumoricidal properties of curcumin. Int J Cancer
2012; 131:E569–78.
145. Yu T, Li J, Qiu Y, et al. 1-phenyl-2-decanoyla-
mino-3-morpholino-1-propanol (PDMP) facili-
tates curcumin-induced melanoma cell apoptosis
by enhancing ceramide accumulation, JNK acti-
vation, and inhibiting PI3K/AKT activation. Mol
Cell Biochem 2012; 361:47–54.
146. Mazzarino L, Silva LF, Curta JC, et al. Curcu-
min-loaded lipid and polymeric nanocapsules
stabilized by nonionic surfactants: an in vitro
and in vivo antitumor activity on B16-F10 mela-
noma and macrophage uptake comparative
study. J Biomed Nanotechnol 2011; 7:406–14.
147. Sun A, Shoji M, Lu YJ, et al. Synthesis of EF24-
tripeptide chloromethyl ketone: a novel
curcumin-related anticancer drug delivery sys-
tem. J Med Chem 2006; 49:3153–8.
148. Mazzarino L, Otsuka I, Halila S, et al. Xyloglu-
can-block-poly(-caprolactone) copolymer nano-
particles coated with chitosan as biocompatible
mucoadhesive drug delivery system. Macromol
Biosci 2014; 14:709–19.
149. Bartel DP. MicroRNAs: target recognition and
regulatory functions. Cell 2009; 136:215–33.
150. Mirzaei H, Gholamin S, Shahidsales S, et al.
MicroRNAs as potential diagnostic and prognos-
tic biomarkers in melanoma. Eur J Cancer 2016;
53:25–32.
151. Schickel R, Boyerinas B, Park SM, et al. Micro-
RNAs: key players in the immune system, differ-
entiation, tumorigenesis and cell death.
Oncogene 2008; 27:5959–74.
152. Salarini R, Sahebkar A, Mirzaei H, et al. Epi-
drugs and epi-miRs: moving beyond current can-
cer therapies. Curr Cancer Drug Targets 2015.
153. Gholamin S, Pasdar A, Khorrami M, et al. The
potential for circulating microRNAs in the diag-
nosis of myocardial infarction: a novel approach
to disease diagnosis and treatment. Curr Pharm
Des 2016; 22:397–403.
154. Ventura A, Jacks T. MicroRNAs and cancer:
short RNAs go a long way. Cell 2009; 136:
586–91.
155. Saini S, Majid S, Dahiya R. Diet, microRNAs
and prostate cancer. Pharmaceut Res 2010; 27:
1014–26.
156. Zhang P, Bai H, Liu G, et al. MicroRNA-33b,
upregulated by EF24, a curcumin analog, sup-
presses the epithelial-to-mesenchymal transition
(EMT) and migratory potential of melanoma
cells by targeting HMGA2. Toxicol Lett 2015;
234:151–61.
157. Toden S, Okugawa Y, Buhrmann C, et al. Novel
evidence for curcumin and boswellic acid-
induced chemoprevention through regulation of
miR-34a and miR-27a in colorectal cancer. Can-
cer Prev Res (Phila) 2015; 8:431–43.
158. Sadeghipour A, Eidi M, Ilchizadeh Kavgani A,
et al. Lipid lowering effect of punica granatum L.
Peel in high lipid diet fed male rats. Evid Based
Complement Alternat Med 2014; 2014:432650
159. Ali S, Ahmad A, Aboukameel A, et al. Increased
Ras GTPase activity is regulated by miRNAs
that can be attenuated by CDF treatment in
pancreatic cancer cells. Cancer Lett 2012;
31917381.
160. Ye M, Zhang J, Zhang J, et al. Curcumin pro-
motes apoptosis by activating the p53-miR-192-
5p/215-XIAP pathway in non-small cell lung
cancer. Cancer Lett 2015; 357:196–205.
161. Zhang J, Du Y, Wu C, et al. Curcumin pro-
motes apoptosis in human lung adenocarcinoma
cells through miR-186* signaling pathway. Oncol
Rep 2010; 24:1217–23.
162. Gao W, Chan JY, Wong TS. Curcumin exerts
inhibitory effects on undifferentiated nasopha-
ryngeal carcinoma by inhibiting the expression
of miR-125a-5p. Clin Sci 2014; 127:571–9.
163. Zhao SF, Zhang X, Zhang XJ, et al. Induction of
microRNA-9 mediates cytotoxicity of curcumin
against SKOV3 ovarian cancer cells. APJCP
2014; 15:3363–8.
164. Yallapu MM, Khan S, Maher DM, et al. Anti-
cancer activity of curcumin loaded nanoparticles
in prostate cancer. Biomaterials 2014; 35:8635–48.
165. Li X, Xie W, Xie C, et al. Curcumin modulates
miR-19/PTEN/AKT/p53 axis to suppress bisphe-
nol A-induced MCF-7 breast cancer cell prolif-
erationPhytother. RES 2014; 28:1553–60.
166. Liang HH, Wei PL, Hung CS, et al. MicroRNA-
200a/b inﬂuenced the therapeutic effects of cur-
cumin in hepatocellular carcinoma (HCC) cells.
Tumour Biol 2013; 34:3209–18.
167. Gao SM, Yang JJ, Chen CQ, et al. Pure curcu-
min decreases the expression of WT1 by upreg-
ulation of miR-15a and miR-16-1 in leukemic
cells. JECCR 2012; 31:27
168. Dhillon N, Aggarwal BB, Newman RA, et al.
Phase II trial of curcumin in patients with
advanced pancreatic cancer. Clin Cancer Res
2008; 14:4491–9.
169. Mahammedi H, Planchat E, Pouget M, et al.
The new combination docetaxel, prednisone and
curcumin in patients with castration-resistant
prostate cancer: a pilot phase II study. Oncology
2016; 90:69–78.
170. Hejazi J, Rastmanesh R, Taleban FA, et al. Effect
of curcumin supplementation during radiother-
apy on oxidative status of patients with prostate
cancer: a double blinded, randomized, placebo-
controlled study. Nutr Cancer 2016; 68:77–85.
M
in
i
R
ev
ie
w
Mirzaei et al. 1695
Int. J. Cancer: 139, 1683–1695 (2016) VC 2016 UICC
